Buprenorphine's unique pharmacodynamic profile makes it useful in opioid use disorder. Which property accounts for its 'ceiling effect' on respiratory depression but not on analgesia?
- A Buprenorphine is a full agonist at kappa receptors, which cause respiratory stimulation that counteracts mu-mediated depression
- B Buprenorphine is a partial agonist at mu-opioid receptors (MOR); respiratory depression requires higher receptor occupancy than analgesia, so the ceiling occurs before full respiratory depression develops ✓
- C Buprenorphine's very slow receptor association rate means it never achieves the concentration needed to activate brainstem respiratory centres
- D Buprenorphine is a biased agonist that preferentially recruits beta-arrestin at MOR in respiratory centres while activating G-protein pathways in analgesic circuits
Explanation
Buprenorphine is a partial agonist at mu-opioid receptors (MOR) with very high receptor affinity but low intrinsic efficacy. The key pharmacodynamic principle is that different physiological effects of MOR activation require different degrees of receptor occupancy and signalling efficacy. Analgesia can be achieved at relatively low receptor activation (partial agonism suffices), whereas respiratory depression requires higher receptor signalling efficacy. Since buprenorphine, as a partial agonist, cannot produce maximal MOR stimulation regardless of dose (i.e., it produces a submaximal response at full receptor occupancy), it reaches a ceiling for respiratory depression below the lethal threshold while still producing clinically meaningful analgesia. This is confirmed by the observation that high-affinity antagonists like naloxone displace buprenorphine and can reverse overdose, and that in opioid-naive individuals buprenorphine's respiratory effects plateau around 2–4 mg sublingual doses.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.